Cue Biopharma, Inc. (CUE) financial statements (2021 and earlier)

Company profile

Business Address 21 ERIE STREET
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:855939
Cash and cash equivalents754421
Short-term investments101518
Other undisclosed cash, cash equivalents, and short-term investments0 0
Restricted cash and investments  0
Receivables11 
Other undisclosed current assets111
Total current assets:886141
Noncurrent Assets
Operating lease, right-of-use asset75
Property, plant and equipment223
Deposits noncurrent assets331
Restricted cash and investments000
Other noncurrent assets011
Total noncurrent assets:12115
TOTAL ASSETS:1007245
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities534
Accounts payable212
Accrued liabilities322
Debt 4 
Deferred rent credit  0
Other undisclosed current liabilities1142
Total current liabilities:16126
Noncurrent Liabilities
Long-term debt and lease obligation21 
Operating lease, liability21
Other undisclosed noncurrent liabilities(0)45
Total noncurrent liabilities:455
Total liabilities:211711
Stockholders' equity
Stockholders' equity attributable to parent795534
Common stock000
Additional paid in capital232163106
Accumulated other comprehensive income (loss)0(0)(0)
Accumulated deficit(153)(109)(72)
Total stockholders' equity:795534
TOTAL LIABILITIES AND EQUITY:1007245

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:331
Operating expenses(48)(40)(40)
Operating loss:(45)(37)(39)
Nonoperating income001
Other nonoperating income 00
Loss from continuing operations before income taxes:(45)(36)(38)
Income tax expense(0)(0)(1)
Net loss available to common stockholders, diluted:(45)(37)(39)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(45)(37)(39)
Other comprehensive income00 
Comprehensive loss:(45)(37)(39)
Other undisclosed comprehensive loss, net of tax, attributable to parent  (0)
Comprehensive loss, net of tax, attributable to parent:(45)(37)(39)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: